Friday, 16 October 2026European Markets

TEIXEIRA DUARTE Stock Was 10.58% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with TEIXEIRA DUARTE (TDSA.LS) jumping 10.58% to €0.12 on Tuesday while PSI rose 1.04% to €6,775.93.

TEIXEIRA DUARTE's last close was €0.10, 4% higher than its 52-week high of €0.10.

About TEIXEIRA DUARTE

Teixeira Duarte, S.A. operates in the construction, concessions and services, real estate, hospitality, distribution, and automotive sectors in Portugal and internationally. The company is involved in the various construction activities, including geotechnical engineering and rehabilitation, buildings, infrastructures, and metalworking, as well as underground, railway, and maritime works; and the provision of concessions and services in various business areas, such as facilities management, facilities services, environment, and education. It also develops real estate properties; and operates hotels in Angola, Mozambique and Portugal. In addition, the company distributes food products through MAXI grocery stores; operates restaurants under the Pastelarias Nilo name; offers pharmacy products through Farmácia Popular stores; provides furniture and decoration products under the Dakaza brand; and distributes and integrates FMCG brands. Further, it sells light and heavy-duty cars, motorcycles, and equipment; and provides technical assistance. Teixeira Duarte, S.A. was founded in 1921 and is headquartered in Oeiras, Portugal.

Earnings Per Share

As for profitability, TEIXEIRA DUARTE has a trailing twelve months EPS of €-0.03.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -7.08%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, TEIXEIRA DUARTE's stock is considered to be oversold (<=20).

More news about TEIXEIRA DUARTE (TDSA.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com